
zzso cell zzso zzso has shown significant promise in animal studies as a potential treatment for zzso Its application in the clinic depends on the results of human zzso Here, we review the published clinical trials of cancer zzso using zzso zzso zzso We begin with a short review of general properties and considerations in the design of such zzso We then review trials by disease zzso Despite great efforts on the part of individual investigative groups, most trials to date have not yielded data from which firm conclusions can be zzso The reasons for this include zzso DC preparation and vaccination zzso use of different zzso zzso variable means of immune assessment, and zzso criteria for defining clinical zzso While extensive animal studies have been conducted using zzso optimal parameters in humans remain to be zzso zzso questions include optimal cell dose, use of mature versus immature zzso for zzso optimal zzso preparation, optimal route, and optimal means of assessing immune zzso It is critical that these questions be answered, as DC therapy is zzso and zzso Cooperation is needed on the part of the many investigators in the field to address these zzso If such cooperation is not forthcoming, the critical studies that will be required to make DC therapy a clinically and commercially viable enterprise will not take place, and this therapy, so promising in zzso studies, will not be able to compete with the many other new approaches to cancer therapy presently in zzso Trials published in print through June 2003 are zzso We exclude single case reports, except where relevant, and trials with so many variables as to prevent interpretation about DC therapy zzso 

